Efficacy, Safety, and Patient Reported Outcomes of Rhenium-Skin Cancer Therapy for Non-Melanoma Skin Cancer: 1-Year Results from the EPIC-Skin Study
This 12-month interim analysis of EPIC-Skin indicates rhenium-SCT is an effective and well-tolerated treatment for shallow basal cell carcinoma and SCC lesions, yielding favorable safety, cosmesis, and patient-satisfaction outcomes. These outcomes underscore the utility of rhenium-SCT as a single-session, noninvasive treatment for NMSC, offering a safe, effective, and efficient alternative to surgery for patients with functional or cosmetic considerations, and/or comorbidities.
Authors
- Giuseppe Cardaci
- Siroos Mirzaei (ORCID: https://orcid.org/0000-0003-2861-6811)
- Kgomotso Mokoala (ORCID: https://orcid.org/0000-0003-3784-4090)
- Martin Heuschkel
- Julia K. Tietze (ORCID: https://orcid.org/0000-0002-3351-8266)
- Mike Sathekge (ORCID: https://orcid.org/0000-0002-2806-0625)
- Cody C. Allison (ORCID: https://orcid.org/0000-0003-3775-0940)
- Angela Hong (ORCID: https://orcid.org/0000-0003-3668-243X)
- Siddhartha Baxi (ORCID: https://orcid.org/0000-0002-6207-1942)
- Nicola Mulholland (ORCID: https://orcid.org/0000-0003-0912-9890)
- Gerhard Dahlhoff
- Saima Vohra
Institutions
- Royal North Shore Hospital (AU)
- Genesis HealthCare (US)
- Hollywood Private Hospital (AU)
- Mission Australia (AU)
- Steve Biko Hospital (ZA)
- PYC Therapeutics (Australia) (AU)
- King's College Hospital NHS Foundation Trust (GB)
- Melanoma Institute Australia (AU)
- University of Rostock (DE)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1016/j.adro.2025.101802
- Citations
- 4
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.42